Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hutchison China MediTech Limited    HCM   KYG4672N1198


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Hutchison China MediTech : Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

share with twitter share with LinkedIn share with facebook
share via e-mail
10/17/2019 | 02:46am EST

LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Cancer Discovery, a journal of the American Association of Cancer Research1. The principal study investigator was Dr. Jeeyun Lee, Associate Professor at the Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 

The research article titled “Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial” in the October 2019 issue of Cancer Discovery details the VIKTORY study, which was designed to classify patients with metastatic gastric cancer based on clinical sequencing and focused on eight different biomarker groups, including MET amplification, to assign patients to one of the 10 associated clinical trials in second-line treatment.

Dr. Lee and colleagues classified 772 patients with gastric cancer and successfully sequenced 715 patients (92.6%). Based on this sequencing, MET amplification was observed in 3.5% of patients (25/715). Of the 10 associated clinical trials under the VIKTORY umbrella, the highest objective response rate (“ORR”) was observed in the MET amplification savolitinib monotherapy trial, which reported an ORR of 50% (10/20, 95% CI: 28.0 – 71.9). Dr. Lee and colleagues concluded that the savolitinib monotherapy trial also met the pre-specified 6-week progression free survival rate, indicating that it is worthy of further exploration in the MET amplification subset of patients with gastric cancer.

Gastric cancer was the third leading cause of cancer related mortality in 2018, causing 783,000 deaths worldwide. The prognosis of patients with metastatic gastric cancer remains extremely poor, with a median overall survival of less than 12 months with cytotoxic chemotherapy.

About Savolitinib

Savolitinib is a potential first-in-class inhibitor of MET, an enzyme which has been shown to function abnormally in many types of solid tumors. Chi-Med designed savolitinib to be a potent and highly selective oral inhibitor, which, through chemical structure modification, addresses human metabolite-related renal toxicity, the primary issue that halted development of several other selective MET inhibitors. In clinical studies to date, involving over 900 patients, savolitinib has shown promising signs of clinical efficacy in patients with MET gene alterations in multiple tumor types with an acceptable safety profile. Chi-Med is currently testing savolitinib in partnership with AstraZeneca in Phase Ib/II studies, in multiple solid tumor indications, both as a monotherapy and in combinations.

About Chi-Med

Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has over 470 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit: www.chi-med.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Chi-Med’s current expectations regarding future events, including its expectations for the clinical development of savolitinib, plans to initiate clinical studies for savolitinib, its expectations as to whether such studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of drug candidate savolitinib to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval, the potential market of savolitinib for a targeted indication and the sufficiency of funding. In addition, as certain studies rely on the use of Tagrisso®, Iressa® and Imfinzi® as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of Tagrisso®, Iressa® and Imfinzi®. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.


Investor Enquiries 
Mark Lee, Senior Vice President+852 2121 8200
Annie Cheng, Vice President+1 (973) 567 3786
David Dible, Citigate Dewe Rogerson+44 7967 566 919 (Mobile)
Xuan Yang, Solebury Trout+1 (415) 971 9412 (Mobile)
Media Enquiries 
UK & EuropeAnthony Carlisle, Citigate Dewe Rogerson+44 7973 611 888 (Mobile)
AmericasBrad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)
Hong Kong & Asia ex-ChinaJoseph Chi Lo, Brunswick+852 9850 5033 (Mobile)
 Zhou Yi, Brunswick+852 9783 6894 (Mobile)
Mainland ChinaSam Shen, Edelman+86 136 7179 1029 (Mobile)
Nominated Advisor 
Atholl Tweedie, Panmure Gordon (UK) Limited+44 (20) 7886 2500


1 Jeeyun Lee, Seung Tae Kim et al.  Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial.  Cancer Discov October 1 2019 (9) (10) 1388-1405; DOI: 10.1158/2159-8290.CD-19-0442.

HCM Hutchison China MediTech tall 129x150.png

Source: Hutchison China MediTech Limited

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13HUTCHISON CHINA MEDITECH : Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
01/13Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi i..
01/06HUTCHISON CHINA MEDITECH : Chi-Med to Present at the 38th Annual JP Morgan Healt..
01/06HUTCHISON CHINA MEDITECH : Chi-Med to Present at JP Morgan Conference
2019HUTCHISON CHINA MEDITECH : Surufatinib Granted Priority Review in China
2019Chi-Med's New Drug Application for Surufatinib in Non-Pancreatic Neuroendocri..
2019Chi-Med's Elunate® (Fruquintinib Capsules) Included in the National Reimburse..
2019HUTCHISON CHINA MEDITECH : Elunate® Included in China NRDL
2019HUTCHISON CHINA MEDITECH : Chi-Med Highlights Presentations at 2019 ESMO Asia
2019Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancrea..
More news
Financials (USD)
Sales 2019 194 M
EBIT 2019 -146 M
Net income 2019 -123 M
Finance 2019 160 M
Yield 2019 -
P/E ratio 2019 -31,4x
P/E ratio 2020 -24,7x
EV / Sales2019 19,3x
EV / Sales2020 18,3x
Capitalization 3 898 M
Duration : Period :
Hutchison China MediTech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 6,55  $
Last Close Price 5,85  $
Spread / Highest target 30,6%
Spread / Average Target 11,9%
Spread / Lowest Target -19,7%
EPS Revisions
Christian Hogg Chief Executive Officer & Executive Director
Chi Keung To Chairman
Enrico Magnanelli Vice President & Head-International Operations
Chig Fung Cheng Chief Financial Officer & Executive Director
Wei Guo Su Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.60%392 596
ROCHE HOLDING AG2.21%289 160
PFIZER3.39%224 187
NOVARTIS-0.29%217 045